RT Generic
T1 Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.
A1 Baniandres-Rodriguez, Ofelia
A1 Vilar-Alejo, Jaime
A1 Rivera, Raquel
A1 Carrascosa, Jose Manuel
A1 Dauden, Esteban
A1 Herrera-Acosta, Enrique
A1 Sahuquillo-Torralba, Antonio
A1 Gomez-Garcia, Fran J
A1 Nieto-Benito, Lula Maria
A1 de la Cueva, Pablo
A1 Lopez-Estebaranz, Jose Luis
A1 Belinchon, Isabel
A1 Ferran-Farres, Marta
A1 Alsina, Merce
A1 Rodriguez-Fernandez-Freire, Lourdes
A1 Carretero, Gregorio
A1 Garcia-Donoso, Carmen
A1 Ballesca, Ferran
A1 Llamas-Velasco, Mar
A1 Herrera-Ceballos, Enrique
A1 Botella-Estrada, Rafael
A1 Ruiz-Genao, Diana Patricia
A1 Riera-Monroig, Josep
A1 Descalzo-Gallego, Miguel Angel
A1 Garcia-Doval, Ignacio
K1 Psoriasis
K1 Registries
K1 Severity of Illness Index
K1 Spain
AB To the Editor: The use of systemic treatments in psoriatic patients during the pandemic has been the subject of extensive debate. In March 2020, weperformed a specific study within the cohort of Biobadaderm Registry, a previously described national, multicenter, prospective cohort. Our primary objective was to analyze the incidence of COVID-19 infections and severeoutcomes in a cohort of psoriatic patients treated with systemic therapies and to compare it with that of the general population. We reviewed all Biobadaderm patient records and contacted the patients when needed. We collected information about current comorbidities related to COVID-19 and COVID-19 outcomes in all active patients of the registry. We used the latest data updated on July 6, 2020.
PB Elsevier
YR 2020
FD 2020-10-26
LK http://hdl.handle.net/10668/16501
UL http://hdl.handle.net/10668/16501
LA en
NO Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J Am Acad Dermatol. 2021 Feb;84(2):513-517
DS RISalud
RD Oct 1, 2025